OBJECTIVE: Mast cells are tissue-resident immune sentinels that are implicated in the pathogenesis of inflammatory joint disease. The aim of this study was to test our hypothesis that complement fragments could be key activators of synovial mast cells in autoimmune arthritis. METHODS: In vivo studies used the murine K/BxN arthritis model, a distal symmetric polyarthritis mediated by IgG immune complexes. Expression of C5aR on synovial mast cells was determined by immunohistochemical and functional studies. C5aR(-/-) and control mast cells were engrafted into mast cell-deficient WBB6 F1-Kit(w) /Kit(W-v) (W/Wv) mice to examine the requirement for this receptor in arthritis. C5aR-dependent activation of mast cells was investigated in C5aR(-/-) animals and in murine and human mast cell cultures. RESULTS: Murine synovial mast cells express functional C5aR. Unlike their wild-type counterparts, C5aR(-/-) mast cells adoptively transferred into W/Wv mice were not competent to restore arthritis, despite equivalent synovial engraftment. Activation of C5aR(-/-) mast cells by K/BxN serum in vivo remained intact, indicating that C5aR is dispensable for normal IgG-mediated triggering. Consistent with this result, cultured mast cells treated with C5a failed to modulate the expression of Fcγ receptors (FcγR) or to otherwise alter the activation threshold. In human mast cells, C5a promoted the production of the neutrophil chemotaxin interleukin-8, and recruitment of neutrophils at 24 hours after serum administration was impaired in C5aR(-/-) mice, suggesting that enhanced neutrophil chemoattractant production underlies the requirement for C5aR on mast cells in arthritis. CONCLUSION: Stimulation via C5aR is required to unleash the proinflammatory activity of synovial mast cells in immune complex arthritis, albeit via a mechanism that is distinct from C5a-modulated expression of FcγR.
OBJECTIVE: Mast cells are tissue-resident immune sentinels that are implicated in the pathogenesis of inflammatory joint disease. The aim of this study was to test our hypothesis that complement fragments could be key activators of synovial mast cells in autoimmune arthritis. METHODS: In vivo studies used the murine K/BxN arthritis model, a distal symmetric polyarthritis mediated by IgG immune complexes. Expression of C5aR on synovial mast cells was determined by immunohistochemical and functional studies. C5aR(-/-) and control mast cells were engrafted into mast cell-deficient WBB6 F1-Kit(w) /Kit(W-v) (W/Wv) mice to examine the requirement for this receptor in arthritis. C5aR-dependent activation of mast cells was investigated in C5aR(-/-) animals and in murine and human mast cell cultures. RESULTS:Murine synovial mast cells express functional C5aR. Unlike their wild-type counterparts, C5aR(-/-) mast cells adoptively transferred into W/Wv mice were not competent to restore arthritis, despite equivalent synovial engraftment. Activation of C5aR(-/-) mast cells by K/BxN serum in vivo remained intact, indicating that C5aR is dispensable for normal IgG-mediated triggering. Consistent with this result, cultured mast cells treated with C5a failed to modulate the expression of Fcγ receptors (FcγR) or to otherwise alter the activation threshold. In human mast cells, C5a promoted the production of the neutrophil chemotaxin interleukin-8, and recruitment of neutrophils at 24 hours after serum administration was impaired in C5aR(-/-) mice, suggesting that enhanced neutrophil chemoattractant production underlies the requirement for C5aR on mast cells in arthritis. CONCLUSION: Stimulation via C5aR is required to unleash the proinflammatory activity of synovial mast cells in immune complex arthritis, albeit via a mechanism that is distinct from C5a-modulated expression of FcγR.
Authors: P J Wolters; J Mallen-St Clair; C C Lewis; S A Villalta; P Baluk; D J Erle; G H Caughey Journal: Clin Exp Allergy Date: 2005-01 Impact factor: 5.018
Authors: T Nakano; T Sonoda; C Hayashi; A Yamatodani; Y Kanayama; T Yamamura; H Asai; T Yonezawa; Y Kitamura; S J Galli Journal: J Exp Med Date: 1985-09-01 Impact factor: 14.307
Authors: Jun-Xia Wang; Angela M Bair; Sandra L King; Ruslan Shnayder; Ya-Fang Huang; Chi-Chang Shieh; Roy J Soberman; Robert C Fuhlbrigge; Peter A Nigrovic Journal: Blood Date: 2012-06-01 Impact factor: 22.113
Authors: Pierre Cunin; Loka R Penke; Jonathan N Thon; Paul A Monach; Tatiana Jones; Margaret H Chang; Mary M Chen; Imene Melki; Steve Lacroix; Yoichiro Iwakura; Jerry Ware; Michael F Gurish; Joseph E Italiano; Eric Boilard; Peter A Nigrovic Journal: J Clin Invest Date: 2017-04-04 Impact factor: 14.808
Authors: Roberto Adachi; Steven A Krilis; Peter A Nigrovic; Matthew J Hamilton; Kyungemee Chung; Shakeel M Thakurdas; Joshua A Boyce; Paul Anderson; Richard L Stevens Journal: J Biol Chem Date: 2012-04-16 Impact factor: 5.157
Authors: William O'Brien; Brian M Fissel; Yukiko Maeda; Jing Yan; Xianpeng Ge; Ellen M Gravallese; Antonios O Aliprantis; Julia F Charles Journal: Arthritis Rheumatol Date: 2016-12 Impact factor: 10.995
Authors: Stephanie M Stanford; Mattias N D Svensson; Cristiano Sacchetti; Caila A Pilo; Dennis J Wu; William B Kiosses; Annelie Hellvard; Brith Bergum; German R Aleman Muench; Christian Elly; Yun-Cai Liu; Jeroen den Hertog; Ari Elson; Jan Sap; Piotr Mydel; David L Boyle; Maripat Corr; Gary S Firestein; Nunzio Bottini Journal: Arthritis Rheumatol Date: 2016-02 Impact factor: 10.995
Authors: Phillip W Askenase; Krzysztof Bryniarski; Vipin Paliwal; Frank Redegeld; Thomas Groot Kormelink; Steven Kerfoot; Andrew T Hutchinson; Henk van Loveren; Regis Campos; Atsuko Itakura; Monika Majewska-Szczepanik; Natsuo Yamamoto; Katarzyn Nazimek; Marian Szczepanik; Wold Ptak Journal: Ann N Y Acad Sci Date: 2015-12 Impact factor: 5.691